SEC Filing Summary: Form 8-K
Business Context and Reporting Period
Company: AIKIDO PHARMA INC. (Note: Request metadata listed "Dominari Holdings Inc.", but the filing text identifies the registrant as AIKIDO PHARMA INC.)
Filing Date: March 26, 2020
Reporting Period: Current report regarding corporate governance events.
Business Context: The Company is a Delaware corporation with its principal executive offices in New York, NY. Its common stock trades on The Nasdaq Capital Market under the symbol "AIKI".
Financial Metrics
This filing is a Form 8-K reporting a specific corporate event (Item 5.08) and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported in this filing is the Board of Directors' decision to schedule the 2020 Annual Meeting of Stockholders. The meeting is planned to be held on or around December 1, 2020. No financial material changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Management Commentary
- Management Action: The Board has decided to hold the Annual Meeting on or around December 1, 2020.
- Next Steps: The Company will announce the definitive date, time, and related deadlines after a final decision is made.
- Compliance: Proxy materials will be filed and mailed as required by law.
- Risks/Contingencies: No specific risks or contingencies are detailed in this filing beyond the standard procedural nature of scheduling an annual meeting.
Key Facts for Investor Verification
- Verify the definitive date and time for the 2020 Annual Meeting of Stockholders once announced by the Company.
- Confirm the Company's ticker symbol is "AIKI" on The Nasdaq Capital Market.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.
- Monitor subsequent filings for the proxy statement containing details on shareholder proposals and director nominations.